Product Launch

Stem Cell Sciences plc
28 February 2006


NEWS

FOR IMMEDIATE RELEASE

Contact: Bill Davis             Hugh Ilyine                 Yvonne Alexander
Chemicon International          Stem Cell Sciences          Weber Shandwick
Public Affairs Manager          Chief Operating Officer
001 678-728-2018                0044 131 662 9829           0044 207 06 0700

     

     Chemicon International and Stem Cell Sciences Announce Launch of ESGRO
                            CompleteTM Product Line
                                         
    - New Grade of Serum and Feeder-Free Media for Mouse Embryonic Stem Cell
                                  Expansion -

ATLANTA, GA, and EDINBURGH, UK - February 28, 2006 - Serologicals Corporation
(NASDAQ: SERO) announced today that Chemicon International, Inc. (Chemicon), its
wholly-owned subsidiary, and Stem Cell Sciences plc (LSE:STEM, SCS) are
launching the ESGRO CompleteTM product line for murine embryonic stem (ES) cell
culture, following the establishment of an exclusive agreement on November 3,
2005.

Chemicon will exclusively market the licensed ESGRO CompleteTM Clonal Grade
Medium for serum-free, feeder-free expansion of mouse ES cells. The product,
developed by SCS's SC Proven division, is the first complete, defined medium
that enables the large-scale, consistent production of mouse ES cells for the
use in world-wide research and drug discovery markets. To compliment the
offering, Chemicon will be releasing other media and reagents needed for routine
mouse ES cell culture that have been specifically engineered and validated for
use in this serum-free system. The ESGRO CompleteTM product line will broaden
Chemicon's offering within the stem cell culture market and will complement the
current portfolio of innovative reagents and technologies that are already being
supplied to its customer base.

"We are very excited about the launch of our first cell culture media product.
This will generate revenue streams in the near term and marks a major milestone
in our development," said Peter Mountford, CEO of Stem Cell Sciences plc.   "The
launch validates our technology and will contribute to the wider adoption of
stem cells within the global drug discovery market.  We look forward to our
continued collaboration with Chemicon and the opportunity to expand the stem
cell culture product offering in due course."

"The ESGRO CompleteTM product line is a great leap forward over the existing
methodologies used by our customers today," said Jeffrey D. Linton, President of
Chemicon and Upstate, which comprise Serologicals' Research Segment. "This is a
culmination of our earlier agreement with Stem Cell Sciences to commercialize
this technology through our Research Segment, and is yet another example of how
Serologicals is a leading company in the stem cell research arena."

                                   -- END --

Stem Cell Sciences plc (SCS) is a global biotechnology company focused on the
development of stem cell technologies. The Company has established a leading
intellectual property (IP) and technology portfolio that enables the commercial
application of stem cells in pharmaceutical and biotechnology drug discovery,
providing the Company with an early-stage revenue stream. In the longer term,
the Company is developing regenerative, cell-based therapies.

Stem Cell Sciences has four business units focused on key sustainable business
strategies. SC Proven provides serum free, cell culture media and reagents that
enable the growth of stem cells. The first commercially available product, a
mouse embryonic stem cell growth medium, has been exclusively licensed for
manufacture and marketing to Chemicon, a division of Serologicals Inc. SC
Licensing licenses its proprietary technologies such as Internal Ribosome Entry
Site (IRES) and Stem Cell Selection for application in laboratory-based research
and discovery. SC Services will provide cell production for research and
high-throughput drug screening. SC Therapies first program is being undertaken
by SCS's Japanese affiliate, which recently announced the exclusive licensing of
human multipotent adipocyte-derived (hMads) for use in an experimental cell
based therapy programme against Duchene's Muscular Dystrophy form the basis for
a degenerative diseases focused pre-clincial programme.

SCS plc is a global Group with operations in the UK, Australia and Japan. Each
company is affiliated with academic stem cell centers of excellence in order to
access and commercialize new IP developing in the field. These include the
Institute of Stem Cell Research, Edinburgh, UK; RIKEN Centre for Development
Biology, Japan and the Australian Stem Cell Centre, Melbourne, Australia.

SCS, which listed on the London Alternative Investment Market in July 2005, was
founded in 1994 to commercialize findings from the Institute of Stem Cell
Research at the University of Edinburgh, UK, and Monash University, Melbourne,
Australia. The Company is a participant in two research projects under the
European Union's Framework Six Programme for Research and Technology Development
and is a contributor to the UK Stem Cells Initiative.

Chemicon International, Inc. offers a broad range of research products,
including specialty reagents, kits, antibodies, and custom products and
services, to customers working in the areas of neuroscience, stem cell biology,
cancer, and infectious disease research. It is also a leading supplier of
monoclonal antibodies, conjugates, antibody blends and molecular-based detection
kits for use in diagnostic laboratories. Chemicon focuses on basic and
biomedical research, drug discovery, and diagnostics, allowing it to serve
thousands of customers worldwide in the academic, clinical, biotechnology, and
pharmaceutical sectors. Acquired in 2003, Chemicon is a Serologicals company,
based in Temecula, CA.

For more information, please visit our website: www.chemicon.com

Serologicals Corporation (NASDAQ: SERO), headquartered in Atlanta, GA., is a
global leader in developing and commercializing consumable biological products,
enabling technologies and services in support of biological research, drug
discovery, and the bioprocessing of life-enhancing products. Our customers
include researchers at major life science companies and leading research
institutions involved in key disciplines, such as neurology, oncology,
hematology, immunology, cardiology, proteomics, infectious diseases, cell
signaling and stem cell research. In addition, Serologicals is the world's
leading provider of monoclonal antibodies for the blood typing industry.
Serologicals employs a total of more than 1,000 people worldwide in three
Serologicals' companies: Chemicon International, headquartered in Temecula, CA,
Upstate Group, LLC, headquartered in Charlottesville, VA. and Celliance
Corporation, headquartered in Atlanta, GA.

For more information, please visit our website: www.serologicals.com

This release contains certain forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Words or phrases such as
"should result," "are expected to," "we anticipate," "we estimate," "we project"
or similar expressions are intended to identify forward-looking statements.
These statements are subject to certain risks and uncertainties that could cause
actual results to differ materially from those expressed in any forward-looking
statements.

You should not place undue reliance on forward-looking statements, since the
statements speak only as of the date that they are made, and the Company
undertakes no obligation to update these statements based on events that may
occur after the date of this press release.

Serologicals is a registered trademark of Serologicals Royalty Company.




                      This information is provided by RNS
            The company news service from the London Stock Exchange